These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 18662175

  • 1. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
    Awa Y, Suzuki H, Hamano S, Okano T, Sakurayama Y, Ohki T, Egoshi K, Ota S, Mori I, Ichikawa T.
    Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T.
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A, Okayama Urological Research Group.
    Scand J Urol Nephrol; 2009 Apr; 43(4):307-14. PubMed ID: 19396723
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H, Naoi M, Sekiyama K, Hamano S, Suzuki N, Tanaka M, Murakami S.
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [Abstract] [Full Text] [Related]

  • 9. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
    Maruyama O, Kawachi Y, Hanazawa K, Koizumi K, Yamashita R, Sugimura S, Honda S, Sugiyama Y, Saitoh T, Noto K.
    Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of naftopidil on nocturia after failure of tamsulosin.
    Oh-oka H.
    Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T.
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [Abstract] [Full Text] [Related]

  • 15. [The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia].
    Ju XB, Wu HF, Su JT.
    Zhonghua Nan Ke Xue; 2002 Jan; 8(4):286-8. PubMed ID: 12491697
    [Abstract] [Full Text] [Related]

  • 16. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S.
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [Abstract] [Full Text] [Related]

  • 17. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N, Tsukamoto T, Iwasawa A, Furuya R, Sonoda T, Mori M, Hokkaido Urological Disorders Conference Writing Group.
    Urol Int; 2009 Sep; 83(1):49-54. PubMed ID: 19641359
    [Abstract] [Full Text] [Related]

  • 18. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 19. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X.
    Chin Med J (Engl); 2007 Mar 05; 120(5):370-4. PubMed ID: 17376305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.